Article

FDA approves treatment for cystinosis

The FDA has approved cysteamine ophthalmic solution (Cystaran, Sigma-Tau Pharmaceuticals) 0.44% for corneal cystine crystal accumulation in patients with cystinosis.

Related Videos
Image credit: Ophthalmology Times; Angiogenesis 2025: Encapsulated cell therapy for MacTel shows long-term efficacy in phase 3 trials
© 2025 MJH Life Sciences

All rights reserved.